The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 39.50
Change: 0.00 (0.00%)
Spread: 1.00 (2.597%)
Open: 39.00
High: 38.70
Low: 38.70
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Director

17 Jun 2014 07:00

RNS Number : 7404J
Venture Life Group PLC
17 June 2014
 



 

 

Venture Life Group plc

("Venture Life" or "the Group")

Appointment of Non-Executive Director

 

Bracknell, UK - 17 June 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces the appointment of Ian Mackinnon to the board as a non-executive director with effect from 16 June 2014. He will chair the Group's Audit and Risk Committee and will also be a member of the Remuneration and Nomination Committees. John Sylvester, who currently chairs the Group's Audit and Risk Committee will be standing down as chair of this committee but will remain a member.

Mr Mackinnon was formerly the Chief Financial Officer and Chief Executive Officer of Swallowfield plc, a leading supplier to global brands in the cosmetics, personal care and household goods sectors. He is also a Fellow of the Institute of Chartered Accountants of England and Wales.

Dr Lynn Drummond, Chair of Venture Life said: "I am pleased to welcome Ian to the board of Venture Life. Ian's experience, particularly of commercial operations in the Far East, will be invaluable as we grow both our brands and manufacturing businesses. We look forward to his contribution to the board."

Ian Mackinnon added "I am excited to be joining this ambitious company and working with it as it executes its growth strategy."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Ian Andrew Mackinnon, age 49 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

IM Advisory Limited

Past directorships

Swallowfield plc and various subsidiaries

Mr Mackinnon has not held any other directorships in the previous five years and he does not hold any ordinary shares in the Group. There are no further disclosures to be made in accordance with Schedule Two paragraph (g) of the AIM Rules in connection with Ian Mackinnon's appointment to the Group's Board.

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0) 1344 742870

 

WG Partners (Broker) Jonathan Gosling

Claes Spång +44 (0) 20 3693 1566

 

Charles Stanley Securities (Nominated Adviser) Phil Davies +44 (0) 20 7649 6000

 

Square1 Consulting

David Bick

Mark Longson +44 (0) 20 7929 5599

 

JW Communications

Julia Wilson +44 (0) 7818 430877

 

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently includes food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEQLFFZQFFBBQ
Date   Source Headline
11th Nov 201911:33 amRNSUltraDEX wins at the Dental Industry Awards 2019
7th Oct 201910:57 amRNSHolding(s) in Company
20th Sep 20197:00 amRNSHalf-year Report - Amendment
19th Sep 20197:00 amRNSInterim Results
17th Jul 20197:00 amRNSCommercial update
11th Jul 20193:33 pmRNSDirector/PDMR Shareholding
8th Jul 20195:02 pmRNSHolding(s) in Company
25th Jun 20198:44 amRNSDirector/PDMR Shareholding
3rd Jun 201911:36 amRNSResult of AGM
17th May 20194:35 pmRNSPrice Monitoring Extension
1st May 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSFinal Results
26th Mar 20195:17 pmRNSHolding(s) in Company
20th Mar 20197:00 amRNSNotice of Results Update
29th Jan 20197:00 amRNSTrading and Commercial Update
5th Dec 20183:26 pmRNSHolding(s) in Company
5th Dec 20188:12 amRNSHolding(s) in Company
23rd Nov 20187:00 amRNSChange of adviser and directorate update
15th Nov 20187:00 amRNSCommercial update
20th Sep 20187:01 amRNSDirectorate Change
20th Sep 20187:00 amRNSHalf-year Report
16th Aug 20187:00 amRNSTrading update & notice of interim results
13th Aug 201812:17 pmRNSHolding(s) in Company
8th Aug 20182:15 pmRNSHolding(s) in Company
8th Aug 20187:00 amRNSCompletion of Placing and Acquisition
7th Aug 20184:54 pmRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201810:10 amRNSHolding(s) in Company
6th Aug 201811:51 amRNSResult of General Meeting
23rd Jul 20184:00 pmRNSHolding(s) in Company
20th Jul 20187:00 amRNSPlacing, proposed acquisition and notice of GM
20th Jul 20187:00 amRNSAppointment of Joint Broker
19th Jul 20183:38 pmRNSHolding(s) in Company
18th Jun 20187:00 amRNSIncreased distribution of UltraDEX in Boots, UK
4th Jun 20187:00 amRNSLloyds Pharmacy to list UltraDEX in UK
23rd May 201812:29 pmRNSResult of AGM
21st May 20187:00 amRNS'1000 Companies to Inspire Britain' 2018 report
9th May 20187:00 amRNSAlliance Pharma contract expansion and extension
8th May 20182:54 pmRNSHolding(s) in Company
30th Apr 20187:00 amRNSUltraDEX update
17th Apr 20187:00 amRNSDirector/PDMR Shareholding
5th Apr 20187:00 amRNSDirector/PDMR Shareholding
27th Mar 20187:00 amRNSDirector/PDMR Shareholding
26th Mar 20187:00 amRNS2018 LTIP and Grant of Options to PDMRs
22nd Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of analyst & investor results briefings
16th Feb 20187:00 amRNSInvestor presentation
13th Feb 20187:00 amRNSCommerical update
31st Jan 20187:00 amRNSTrading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.